{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:07:40Z","timestamp":1789614460126,"version":"build-2803163510"},"reference-count":19,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Although amiodarone is an effective treatment for severe paediatric arrhythmias, uncertainties about adverse effects such as hypotension, bradycardia and excessive serum drug concentrations persist. Therefore, the aims of this study were to: (a) determine serum concentrations of intravenous (IV) amiodarone following a widely implemented dosing regimen of 5\u2005mg\/kg bolus plus a 10\u2005mg\/kg\/day continuous infusion and (b) generate descriptive data on safety parameters such as hypotension, bradycardia or corrected QT (QTc) prolongation during this regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Prospective observational study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Paediatric intensive care unit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>Twenty paediatric patients (median age, 0.23\u2005years; range, 6\u2005days\u201315.04\u2005years) with arrhythmia secondary to or without cardiac surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>None.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>Amiodarone serum concentrations, blood pressure, heart rate, QTc intervals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Amiodarone serum concentrations increased markedly during bolus, followed by rapid decreases during maintenance infusion. All patients had serum concentrations regarded as effective in adults (median concentration range: 1.30\u20132.06\u2005\u00b5M\/L during maintenance phase). Amiodarone suppressed arrhythmias in 18 (90%) patients. Mean QTc intervals for pretherapy, during and post-therapy periods were 443\u2005ms, 458\u2005ms and 467\u2005ms, respectively. Eight patients had hypotension.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Amiodarone was effective in the majority of children in this small cohort.<\/jats:p><\/jats:sec>","DOI":"10.1136\/archdischild-2013-304483","type":"journal-article","created":{"date-parts":[[2013,9,20]],"date-time":"2013-09-20T08:35:18Z","timestamp":1379666118000},"page":"989-993","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacokinetics of intravenous amiodarone in children"],"prefix":"10.1136","volume":"98","author":[{"given":"Sergej","family":"Ramusovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"L\u00e4er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Meibohm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian B","family":"Lagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2013,9,19]]},"reference":[{"key":"2023090603500786000_98.12.989.1","unstructured":"EMA. Revised provisional priority list for studies into off-patent paediatric medicinal products, 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Other\/2013\/06\/WC500143970.pdf (accessed 27 Aug 2013)."},{"key":"2023090603500786000_98.12.989.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.110.953356"},{"key":"2023090603500786000_98.12.989.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.534149"},{"key":"2023090603500786000_98.12.989.4","first-page":"771","article-title":"Pharmacodynamic studies of amiodarone and its active N-desethyl metabolite","volume":"8","author":"Nattel","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"key":"2023090603500786000_98.12.989.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-003-1302-z"},{"key":"2023090603500786000_98.12.989.6","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(94)90746-3"},{"key":"2023090603500786000_98.12.989.7","doi-asserted-by":"publisher","DOI":"10.1007\/BF02310328"},{"key":"2023090603500786000_98.12.989.8","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00591-9"},{"key":"2023090603500786000_98.12.989.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-002-0276-3"},{"key":"2023090603500786000_98.12.989.10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.109.901629"},{"key":"2023090603500786000_98.12.989.11","doi-asserted-by":"publisher","DOI":"10.1007\/BF02083144"},{"key":"2023090603500786000_98.12.989.12","unstructured":"U.S. Department of Health and Human Services FDA. Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation. http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/UCM174090.pdf (accessed 19 Nov 2012)."},{"key":"2023090603500786000_98.12.989.13","unstructured":"Fanaroff AA Martin RJ . Neonatal perinatal medicine: diseases of the fetus and infant. St. Louis: Mosby, 2002."},{"key":"2023090603500786000_98.12.989.14","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00595-1"},{"key":"2023090603500786000_98.12.989.15","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(85)90377-7"},{"key":"2023090603500786000_98.12.989.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-010-0047-7"},{"key":"2023090603500786000_98.12.989.17","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(87)90492-3"},{"key":"2023090603500786000_98.12.989.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-008-0683-4"},{"key":"2023090603500786000_98.12.989.19","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(84)90195-4"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2013-304483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T10:51:25Z","timestamp":1693997485000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2013-304483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,19]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,11,12]]},"published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1136\/archdischild-2013-304483"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2013-304483","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,19]]}}}